SSY Group Wins Series of NMPA Approvals, Expands High-Value Generics Portfolio

SSY Group ( (HK:2005) ) just unveiled an announcement.

SSY Group has secured multiple new drug production and registration approvals from China’s National Medical Products Administration, strengthening its pipeline in ophthalmic, cardiovascular and anti-influenza therapies. The group is the second PRC entity approved to produce Emedastine Difumarate Eye Drops for allergic conjunctivitis and the third to gain approval for Perindopril Arginine Tablets for hypertension and congestive heart failure.

The company also obtained approvals for Peramivir and Sodium Chloride Injection for treating influenza A and B, and for Bumetanide Injection for hypertension, edematous diseases and various electrolyte and renal-related conditions. These consistency-evaluated approvals broaden SSY Group’s injectable and oral product mix, potentially enhancing its competitive position in China’s hospital and prescription drug markets and supporting future revenue growth through an expanded high-value generics portfolio.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company focused on developing and manufacturing chemical drugs for the Chinese market. The group’s portfolio includes treatments for cardiovascular conditions, infectious diseases and other therapeutic areas, with a strategy centered on securing regulatory approvals and consistency evaluations from China’s National Medical Products Administration to compete in the domestic generics and specialty drug segments.

Average Trading Volume: 9,681,465

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.85B

For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.